RPR 127963
Alternative Names: RPR 127963ELatest Information Update: 04 Jul 2002
At a glance
- Originator Aventis
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis; Glioblastoma
Most Recent Events
- 17 Apr 2000 New profile
- 17 Apr 2000 Preclinical development for Coronary artery restenosis in USA (Unknown route)
- 17 Apr 2000 Preclinical development for Glioblastoma in USA (Unknown route)